Age has been the risk factor most consistently associated with the development of tardive dyskinesia (TD). Increased rates of prevalence, severity and persistence of TD are associated with increasing age. Interpretation of true prevalence rates is complicated by reports of idiopathic spontaneously occurring movement disorders in the elderly. Additionally, elderly persons may suffer from serious medical conditions which may predispose them to develop drug-induced or spontaneous movement disorders. To evaluate the incidence, outcome of and vulnerability to movement disorders in the elderly, 400 patients over the age of 55 will be evaluated prospectively while receiving neuroleptic treatment. Half the sample will be starting on neuroleptics for the first time at study entry and half will have had prior neuroleptic exposure; however, these will have been neuroleptic-free for at least one month. After a drug-free baseline assessment, patients will be reexamined every three months for 4 years. Medication will be withdrawn every six months to assess covert TD. Patients meeting criteria for abnormal movement case definition will receive a medical and neurological work-up to identify possible alternative causes of the movement disorder.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH040015-03
Application #
3377878
Study Section
(LCRB)
Project Start
1986-03-01
Project End
1990-02-28
Budget Start
1988-04-01
Budget End
1989-02-28
Support Year
3
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Long Island Jewish Medical Center
Department
Type
DUNS #
City
New Hyde Park
State
NY
Country
United States
Zip Code
11040
Kane, J M (1999) Management strategies for the treatment of schizophrenia. J Clin Psychiatry 60 Suppl 12:13-7
Kane, J M (1999) Tardive dyskinesia in affective disorders. J Clin Psychiatry 60 Suppl 5:43-7;discussion 48-9
Woerner, M G; Alvir, J M; Saltz, B L et al. (1998) Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 155:1521-8
Woerner, M G; Alvir, J M; Kane, J M et al. (1995) Neuroleptic treatment of elderly patients. Psychopharmacol Bull 31:333-7
Woerner, M G; Saltz, B L; Kane, J M et al. (1993) Diabetes and development of tardive dyskinesia. Am J Psychiatry 150:966-8
Saltz, B L; Woerner, M G; Kane, J M et al. (1991) Prospective study of tardive dyskinesia incidence in the elderly. JAMA 266:2402-6
Saltz, B L; Kane, J M; Woerner, M G et al. (1989) Prospective study of tardive dyskinesia in the elderly. Psychopharmacol Bull 25:52-6
Kane, J M; Woerner, M; Lieberman, J (1988) Epidemiological aspects of tardive dyskinesia. Encephale 14 Spec No:191-4
Kane, J M; Woerner, M; Lieberman, J (1988) Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 8:52S-56S